Novel β-Secretase Cleavage of β-Amyloid Precursor Protein in the Endoplasmic Reticulum/Intermediate Compartment of NT2N Cells

Abraham S.C. Chyung,* Barry D. Greenberg,³ David G. Cook,* Robert W. Doms,* and Virginia M.-Y. Lee*

*Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104; and ³Cephalon, Incorporated, West Chester, Pennsylvania 19380

Abstract. Previous studies have demonstrated that NT2N neurons derived from human embryonal carcinoma cell line (NT2) constitutively process the endogenous wild-type β-amyloid precursor protein (APP) to amyloid β peptide in an intracellular compartment. These studies indicate that other proteolytic fragments generated by intracellular processing must also be present in these cells. Here we show that the NH2-terminal fragment of APP generated by β-secretase cleavage (APPβ) is indeed produced from the endogenous full length APP (APPFL). Pulse–chase studies demonstrated a precursor–product relationship between APPFL and APPβ as well as intracellular and secreted APPβ fragments. In addition, trypsin digestion of intact NT2N cells at 4°C did not abolish APPβ recovered from the cell lysates. Furthermore, the production of intracellular APPβ from wild-type APP appears to be a unique characteristic of postmitotic neurons, since intracellular APPβ was not detected in several non-neuronal cell lines. Significantly, production of APPβ occurred even when APP was retained in the ER/intermediate compartment by inhibition with brefeldin A, incubation at 15°C, or by expression of exogenous APP bearing the dixilysine ER retrieval motif.

Amyloid β (Aβ) peptides are the building blocks of the amyloid fibrils found in neuritic plaques and vascular deposits that accumulate in the brains of patients with Alzheimer’s disease (AD: Selkoe, 1994). Aβ is derived from proteolytic processing of one or more isoforms of the amyloid precursor protein (APP; Kang et al., 1987). APP isoforms are alternatively spliced type I transmembrane glycoproteins that are encoded by a single gene on human chromosome 21 (Kang et al., 1987; St. George-Hyslop et al., 1987). The 39–43-amino acid-long Aβ sequence begins in the ectodomain of APP and extends into the transmembrane region (see Fig. 1). Of the three major Aβ-containing isoforms encoded by the APP gene (i.e., APP695, APP751, and APP770; Kang et al., 1987; Kitaguchi et al., 1988; Ponte et al., 1988; Tanzi et al., 1988), APP695 is expressed almost exclusively by neurons of the central and peripheral nervous systems (Golde et al., 1990; Kang and Müller-Hill, 1990; Ariai et al., 1991).

Newly synthesized APP matures in the endoplasmic reticulum and the Golgi apparatus, acquiring N- and O-linked carbohydrates, tyrosine sulfates (Weidemann et al., 1989; Oltersdorf et al., 1990), and phosphates (Oltersdorf et al., 1990; Suzuki et al., 1992; Knops et al., 1993). Several pathways of APP metabolism have been described in cultured cells, and evidence suggests that the relative importance of each pathway depends on the cell type. For example, non-neuronal cells preferentially process APP by the α-secretase pathway, which cleaves APP within the NH2-terminus of Aβ, thereby precluding the formation of Aβ (Esch et al., 1990; Sisodia et al., 1990). The putative α-secretase enzyme(s) is active at or near the cell surface, causing the NH2-terminal fragment (APPα) to be quickly secreted. In contrast, neuronal cells process a much larger portion of APP by the β-secretase pathway(s), which generate intact Aβ by the combined activity of two enzyme classes. The β-secretase(s) cleaves APP at the NH2 terminus of the Aβ domain releasing a distinct NH2-terminal fragment (APPβ). In addition, the γ-secretase(s) cleaves APP at alternative sites of the COOH terminus, generating species of Aβ that are either 40 (Aβ40) or 42 amino acids long (Aβ42; Seubert et al., 1993; Suzuki et al., 1994; Turner et al., 1996).

Although the identities of the putative α-, β-, and γ-secretases remain speculative, and the precise subcellular localization of their activity is poorly understood, in vitro studies have suggested the existence of at least two
β-secretase pathways. In the endosomal/lysosomal pathway, APP targeted to the cell surface is endocytosed and delivered to endosomes and lysosomes where β- and γ-cleavages can occur (Golde et al., 1992; Haass et al., 1992a; Nordstedt et al., 1993; Koo and Squazzo, 1994; Lai et al., 1995; Perez et al., 1996). The alternative β-secretory pathway is predicted to generate Aβ in Golgi-derived vesicles, most likely secretory vesicles, before secretion (Haass et al., 1995a; Higaki et al., 1995; Perez et al., 1996; Thinakaran et al., 1996b). Whether these pathways operate in the same or different cell types is not known, nor is the biological importance of each pathway for the production of Aβ in vivo understood.

Recently, we showed that both Aβ_{40} and Aβ_{42} are produced intracellularly from endogenous wild-type APP695 by cultured postmitotic central nervous system (CNS) neuronal cells (NT2N) that are induced to differentiate from a human teratocarcinoma cell line (NT2) by treatment with retinoic acid (Pleasure et al., 1992; Pleasure and Lee, 1993; Wertkin et al., 1993; Turner et al., 1996). To date, the human-derived NT2N neuron is the only cell line documented to generate intracellular Aβ_{40} and Aβ_{42} before their eventual release into the medium (Turner et al., 1996). Because neurons are the cell type most adversely affected by AD, the NT2N neurons represent a unique system for the study of intracellular β-secretase pathways in a human neuronal model. An essential first step in the analysis of such pathways is the identification of the pro teaseolytic fragments that are the products of these cleavages. We report here that in addition to Aβ_{40} and Aβ_{42}, the NH2-terminal fragment generated by β cleavage (i.e., APPβ) is produced intracellularly in NT2N neurons before secretion. More significantly, we demonstrate that novel β-secretase activity occurs in the ER/intermediate compartment (IC) of neuronal cells using inhibition with Brefeldin A (BFA), incubation at 15°C, and expression of exogenous APP bearing the dilsyline ER-retrieval motif.

Materials and Methods

Cell Culture

NT2 cells derived from a human embryonal carcinoma cell line (Ntera 2/c1.D1) were grown and passaged twice weekly in Opti-Mem (Life Technologies, Inc., Gaithersburg, MD) supplemented with 5% FBS and penicillin/streptomycin (P/S) as described previously (Pleasure et al., 1992; Pleasure and Lee, 1993). To begin differentiation, 2.5 × 10^6 cells were seeded in a 75-cm² (T75) flask and fed with DME HG (Life Technologies, Inc.) containing 10 μM retinoic acid, 10% FBS, and P/S twice weekly for 5 wk. The cells in a single T75 flask were then replated at a lower density in T225 flasks for 10 d (Replate 1 cells). Greater than 99% pure NT2N neurons were then obtained by enzymatic treatment and mechanical dislodgment of Replate 1 cells and replated at a density of 6 × 10^5 cells/10-cm dish previously coated with polylysine and Matrigel (Pleasure et al., 1992). The NT2N neurons were maintained in medium consisting of one part conditioned medium and one part DME HG containing 10% FBS and P/S. For experiments involving the incubation of NT2N neurons at 15°C for 16 h, regular medium containing DME HG and 10% FBS was replaced by DME HG containing 25 mM Hepes, 10% FBS, and P/S. Cultures of NT2N neurons were used for experiments when they were between 3 to 4 wk old. CHO695 cells, a gift from Dr. S. Sisodia (Johns Hopkins University School of Medicine, Baltimore, MD), were grown and passaged three times per week in α-MEM (Life Technologies, Inc.) supplemented with 10% FBS and P/S. M17 cells were grown and passaged once per week in Opti-Mem (Life Technologies, Inc.) containing 10% iron-enriched calf serum and P/S.

Metabolic Labeling, Gel Electrophoresis, Immunoblotting, and Quantitation

Cultured NT2 neurons were starved in methionine-free DME HG (Life Technologies, Inc.) for 30 min before incubation in fresh, methionine-free DME HG containing 0.5 μCi/ml of [35S]methionine (sp act 1,000 Ci/mmol; NEN-Du Pont, Boston, MA). For steady-state labeling studies, NT2N neurons were labeled with [35S]methionine continuously for 16 h. For pulse-chase studies, cells were labeled with [35S]methionine for 1 h, washed twice with methionine-containing DME, and then chased in the same medium for 0 to 24 h. APPβ2, APPα, and APPβ were separated on 7.5% Laemmli SDS-PAGE gels, and Aβ and p3 were separated on 10/ 16.5% step-gradient Tris-tricine gels. These gels were either stained with Coomassie brilliant blue R (Pierce, Rockford, IL) and dried or transferred to nitrocellulose membranes and dried before exposure to PhosphorImager plates (Molecular Dynamics, Sunnyvale, CA) for 3-5 d. The nitrocellulose replicas containing the immunoprecipitates were further probed with different antibodies, as described previously (Wertkin et al., 1993). Quantitation of bands in the autoradiogram was performed using the ImageQuant software (Molecular Dynamics) as described previously (Turner et al., 1996). Radiolabeled proteins in SDS-PAGE gels and nitrocellulose replicas were also analyzed by standard autoradiographic methods. All experiments were repeated between three to six times.

Sample Preparation and Serial Immunoprecipitations

Cell lysates were prepared as described elsewhere (Golde et al., 1992). Protein concentration was determined by the bicinchoninic acid procedure (Pierce). Media were centrifuged at 100,000 g for 1 h at 4°C before immunoprecipitation. Both cell lysates and media were precleared with protein A-Sepharose (Pharmacia Fine Chemicals, Piscataway, NJ) in RIPA buffer (Molecular Dynamics) for 30 min before incubation in fresh, methionine-free media. For experiments involving the incubation of NT2N neurons and deglycosylation of Immunoprecipitated APPβ

BFA Treatment of NT2N Neurons and Deglycosylation of Immunoprecipitated APPβ

NT2N neurons were pretreated with 20 μg/ml of BFA for 1 h before the addition of 0.5 μCi/ml of [35S]methionine to the cultures for 16 h in the absence or presence of BFA. The cell lysates and media were processed for immunoprecipitation as described above. For deglycosylation of APPβ, the immunoprecipitates containing APPβ were washed twice in sodium phosphate buffer (20 mM, pH 7.2) and boiled for 2 min in 10 μl of 1% SDS. The samples were then boiled for an additional 2 min after adding 90 μl of sodium phosphate buffer with sodium azide (10 mM, pH 7.2), EDTA (50 mM, pH 7.2), and n-Octylglucoside (0.5%, wt/vol). After the denaturation step as described, deglycosylation was initiated by the addition of 2 μl neuraminidase (Arthrobacter; Boehringer Mannheim, Indianapolis, IN), 2.5 μl O-Glycosidase (Boehringer Mannheim), and 0.4 U N-Glycosidase F (Boehringer Mannheim). The samples were then incubated at 37°C for 18 h, and deglycosylated APPβ was run on 7.5% SDS-PAGE gels as described above. For endoglycosidase H (Endo H) sensitivity test, cell lysates and media were immunoprecipitated with Karen as described. The immunoprecipitates were then recovered in 100 μl 60 mM phosphate buffer, pH 5.7, and incubated with 4 μl Endo H (Boehringer Mannheim) or vehicle at 37°C for 18 h. The samples were then run on 7.5% SDS-PAGE gels as described above.
Antibodies for Immunoprecipitation and Immunoblotting

The antibodies used in this study and their epitope specificities are summarized in Fig. 1. Briefly, Karen is a goat polyclonal antisera raised to the large, secreted NH2-terminal fragment of APP, and antibody 53 is a rabbit polyclonal antisera raised to a synthetic peptide corresponding to the amino acid sequence SEVKM. Antibody 53 binds specifically to the free COOH terminus of APP and was generously donated by Dr. Sam Gandy (Cornell University School of Medicine, New York, NY). Also used in this study were three mAbs to Aβ that are specific for residues 1–17 (6E10; Kim et al., 1988, residues 1–10 (Ban50; Suzuki et al., 1994), and residues 18–25 (4G8; Kim et al., 1988).

Preparation of SFV-bearing pSFV-1(APP695) and pSFV-1(APP695 ΔKK)

The lysine motif was introduced into APP695 by standard PCR site-directed mutagenesis of pSFV-1(APP695) using primers 5'-CGAAACCACCGTGAGCTCCTT-3' and 5'-TTAACC GGCTAGTTCTGCTTTCTCAAGAACTTGT-3'. The mutation-containing PCR fragment was isolated by digestion with BamHI and XmaI and then ligated into pSFV(APP695) to yield pSFV(APP695 ΔKK). All pSFV-1 constructs, including a pSFV helper plasmid with SFV structural genes, were linearized by digestion with SpeI and then used as a template for RNA synthesis with SP6 RNA polymerase. Co-electroporation of RNA from the expression vector and helper plasmid into BHK cells yielded an infectious, replication-defective virus that was harvested 24 h later (Liljestrom and Garoff, 1991). Accurate determination of viral stock titers was made as described elsewhere (Cook et al., 1996). For all infection experiments, ~1 x 10^6 NT2N neurons per 35-mm dish were infected in serum-free medium at a multiplicity of infection (MOI) of 7–10. When called for, 20 μg/ml BFA was added after the completion of the infection step.

Results

NT2N Neurons Exhibit Intracellular β-Secretase Activity

Our previous studies have demonstrated that NT2N cells produce intracellular Aβ (Wertkin et al., 1993; Turner et al., 1996). To determine if intracellular APPβ (Fig. 1) can also be recovered from these cells, samples of cell lysate were immunoprecipitated with Karen (an antiserum raised to the NH2-terminal region of APP). Then, the presence of APPβ in the immunoprecipitate was determined by immunoblot analysis using 53 (a polyclonal antibody specific for the free COOH terminus of APPβ). We found that 53 detects a single band of ~95 kD (Fig. 2 a). That this 95-kD APP fragment is indeed APPβ, cleaved at the β-secretase site, was further substantiated by (a) the inability of 369W, an antibody specific for the COOH terminus of APP, to recognize this fragment; (b) the inability of 6E10, an antibody specific for the first 10 amino acid residues of Aβ, to detect this fragment; (c) the binding of Karen, an antibody that recognizes all APP species, to this fragment; (d) the fact that this intracellular APP fragment is ~11–12 kD smaller than APPFL (Fig. 2 a); and (e) the detection of the same 95-kD APP fragment using a different antibody specific for APPβ (i.e., 192; Seubert et al., 1992; and data not shown). To determine if APPβ is secreted, media from

Figure 2. NT2N neurons produce intracellular APPβ and Aβ. To demonstrate the presence of APPβ, samples of cell lysate and medium were collected from NT2N cultures and processed for immunoprecipitation (IP) with Karen, a polyclonal antibody that recognizes epitopes within the large ectodomain of APP. The presence of APPβ, APPα, APPα/β, and APPFL was detected by immunoblotting (IB) with the corresponding antibodies (A). To show that Aβ but not p3 is produced intracellularly, NT2N neurons were radiolabeled with [35S]methionine for 16 h. The cell lysate and the medium were then processed for immunoprecipitation with 4G8, a mAb that binds to both Aβ and p3, or Ban50, a mAb that recognizes only Aβ (B). Immunoprecipitates of Aβ and p3 were separated by electrophoresis in 10/16.5% step-gradient Tris-tricine gels. M, mature APPFL; I, immature APPFL.
NT2N neurons were again immunoprecipitated with Karen and subsequently immunoblotted with various antibodies (Fig. 2a). We found that APPβ was readily detected in the media of NT2N neurons and that it comigrated with APPβ recovered from the cell lysates. However, as expected, APPβ migrated more slowly than the product of γ-secretase cleavage (APPα), which was also recovered from the media.

The detection of intracellular APPβ and Aβ in NT2N neurons is consistent with our view that both β- and γ-secretase activities occur in an intracellular compartment. The absence of intracellular APPα, however, suggests that the majority or all of the α-secretase activity occurs at a different site. To further confirm that the β-secretase pathway, but not the α-secretase pathway, occurs inside these cells, we examined the cell lysate of NT2N neurons for the products of these respective pathways: Aβ, which is generated by β- and γ-secretase cleavages; and p3, a product of α- and γ-secretase cleavages. To do this, we immunoprecipitated the cell lysates of metabolically labeled NT2N neurons with mAbs that can distinguish between these peptides: 4G8 recognizes both Aβ and p3; Ban50, however, binds only to Aβ and not p3 (Fig. 2b). Our data clearly demonstrate that Aβ, but not p3, is produced intracellularly. The p3 fragment was not detected in cell lysates even after prolonged exposure of the film. By contrast, both Aβ and p3 were readily recovered from the media. This observation supports previous findings that the α-secretase pathway occurs at or near the plasma membrane (Haass et al., 1992a, 1995b; Sisodia, 1992).

To determine if the recovery of APPβ from the cell lysates reflects its intracellular origin or its association with the cell surface, we treated cultures of NT2N neurons with trypsin at 4°C. Under such conditions, cell surface-associated but not intracellular APPβ should be proteolyzed. Fig. 3 shows that a similar amount of APPβ was recovered from NT2N neurons regardless of trypsin treatment (Fig. 3, compare lanes 1 and 2). By contrast, when the NT2N neurons were treated with trypsin and 0.1% Triton X-100, intracellular APPβ was completely eliminated (Fig. 3, lane 3). This experiment provides evidence that the APPβ recovered from the NT2N cell lysate is indeed produced in an intracellular compartment.

**Intracellular APPβ Derived from Wild-Type APP Is Detected Only in Cells with a CNS Phenotype**

To determine if other cell types are capable of producing intracellular APPβ, the following cell lines were included in this study for comparison: (a) retinoic acid-naive NT2 cells, the undifferentiated precursors of the NT2N neurons that express high levels of the APP751 and APP770 isoforms; (b) Chinese hamster ovary (CHO) cells stably transfected with APP695; and (c) human M17 neuroblastoma cells. Approximately 800 μg of total protein collected in the cell lysates and each lysate was first immunoprecipitated with Karen and then immunoblotted with either antibody 53 to detect APPβ (Fig. 4a) or Karen to detect all forms of APP (Fig. 4b). We found that while all four cell types expressed detectable levels of APPβ, the NT2N neuron was the only cell type capable of producing detectable levels of intracellular APPβ (Fig. 4a). However, both NT2N neurons and stably transfected CHO cells expressing APP695, but neither NT2 cells nor the M17 neuroblastoma cells, secreted APPβ, raising the possibility that secretion of APPβ may be isoform specific. While our data does not preclude low levels of intracellular β-secretase activity or faster rate of APPβ secretion in these cell lines, the evidence clearly indicates that the fraction of APP processed by β-secretase(s) as well as the subcellular site(s) of this activity may be strongly cell-type dependent.

**NT2N Neurons Produce Intracellular APPβ Before Secretion**

The experiments shown in Figs. 2–4 demonstrated that intracellular APPβ can be detected in NT2N neurons. These data suggest that APPβ may be generated inside the cell before secretion. To demonstrate unequivocally that a precursor–product relationship exists between intracellular and secreted APPβ, we adopted the following approaches. In

---

**Figure 3.** APPβ is produced intracellularly in NT2N neurons. Culture dishes containing >99% pure NT2N cells were metabolically labeled with [35S]methionine for 16 h. Cells were rinsed twice with PBS and then incubated on ice for 20 min with PBS alone (lane 1), with 10 μg/ml trypsin (lane 2), or with 10 μg/ml trypsin and 0.1% Triton X-100 (lane 3). The cells were processed for immunoprecipitation with the anti-APPβ antibody 53, as described in Materials and Methods.

**Figure 4.** Intracellular APPβ is observed only in NT2N neurons. Samples of cell lysate and medium collected from cultures of NT2N, NT2, M17, and CHO cells stably expressing APP695 (CHO695) were processed for immunoprecipitation with the antibody Karen. The immunoprecipitates were separated by SDS-PAGE gels and transferred onto nitrocellulose replicas. APPβ present in the cell lysates and the media were detected by immunoblotting with the anti-APPβ antibody 53 (A). After stripping the nitrocellulose replica in A with 0.1% SDS, the blot was reprobed with Karen to detect all APP ectodomain species (B).
our first approach, NT2N neurons were washed with fresh medium, and then the amount of intracellular as well as secreted APPβ and APPα were measured over an 8-h period. This was accomplished by immunoprecipitation of cell lysates and media collected at the times indicated were immunoprecipitated with Karen. The immunoprecipitates were separated by SDS-PAGE and then transferred onto nitrocellulose membranes. APPβ was identified in immunoblots using the antibody 53. APPα was detected using the antibody 6E10. APPFL and APPα/β were recognized by Karen.

Figure 5. NT2N neurons produce intracellular APPβ before secretion. Cultures of NT2N neurons were washed and fresh medium was replenished before measuring the amount of intracellular and secreted APPβ over an 8-h period. Cell lysate and medium collected at the times indicated were immunoprecipitated with Karen. The immunoprecipitates were separated by SDS-PAGE and then transferred onto nitrocellulose membranes. APPβ was identified in immunoblots using the antibody 53. APPα was detected using the antibody 6E10. APPFL and APPα/β were recognized by Karen.

Figure 6. Pulse–chase labeling demonstrates that intracellular APPβ is produced in an intracellular compartment before secretion in NT2N neurons. NT2N neurons were pulse labeled with [35S]methionine for 1 h and chased for different lengths of time (Fig. 6). We found that after 1 h of chase time, full length APP (APPFL) immunoprecipitated from the cell lysate began to decline, while the intracellular level of APPβ continued to increase until 4 h, after which it also declined (Fig. 6, a and c). This lag in maximum production of intracellular, radiolabeled APPβ supports the idea that APPβ is produced intracellularly from APPFL by β-secretase cleavage. Finally, the 1-h delay in the secretion of APPβ into the medium as well as the accumulation of this fragment with increasing chase time supports a temporal relationship between APPβ that is produced intracellularly and APPβ that is secreted into the medium (Fig. 6, b and d). Therefore, we conclude that APPβ is produced in an intracellular compartment in NT2N neurons before secretion.

Intracellular β-Cleavage in NT2N Neurons Occurs in a pre-Golgi Compartment

Since APPβ is produced in an intracellular compartment in NT2N neurons, we sought to identify the subcellular site(s) of β-secretase cleavage. Therefore, NT2N neurons were metabolically labeled with [35S]methionine in the presence or absence of 20 μg/ml BFA (Fig. 7). BFA is a pharmacological agent that causes a redistribution of the Golgi.
into the ER (Doms et al., 1989; Lippincott-Schwartz, 1989; Pelham, 1991). In the absence of BFA, APPFL, APPβ, and Aβ were recovered from the cell lysates, while APPα, APPβ, and Aβ were detected in the media of NT2N neurons (Fig. 7, a–c, lanes 1 and 3). Surprisingly, in the presence of BFA, not only APPFL but also APPβ and Aβ continued to be recovered from NT2N cell lysates (Fig. 7, a–c, lane 2). The effectiveness of BFA was verified by the fact that the secretion of APPα, APPβ, and Aβ into the medium was completely abolished in its presence (Fig. 7, a–c, lane 4). Furthermore, we found that APPβ recovered from BFA-treated cells (Fig. 7 b, lane 2) migrate with an accelerated electrophoretic mobility compared to APPβ from nontreated cells (Fig. 7 b, lane 1), suggesting that this fragment may have been derived from immature APP. Indeed, the faster mobility of mature APPβ in the presence of BFA (Fig. 7 a, compare M of lanes 1 and 2) indicates that this agent blocks APP from acquiring at least some of the posttranslational modifications. Thus, Aβ may be generated from immature as well as mature forms of APP.

We sought next to determine if incomplete maturation of APP is indeed the cause of the shift in electrophoretic mobility of the APPβ fragment generated in the presence of BFA. Therefore, NT2N cells were metabolically labeled with [35S]methionine in the presence or absence of BFA, and APPβ immunoprecipitated from the cell lysate was incubated with N-glycosidase F (Nglyc F), an enzyme that removes N-linked carbohydrate chains. As shown, APPβ from BFA-treated NT2N neurons (Fig. 8 a, lane 1) migrated more quickly than APPβ recovered from untreated cells (Fig. 8 a, lane 2). After digestion with Nglyc F, APPβ demonstrated a mobility downshift in SDS-PAGE (Fig. 8 a, compare lanes 2 and 4). However, APPβ from BFA-treated cells (Fig. 8 a, lane 3) still migrated faster than APPβ from nontreated cells (Fig. 8 a, lane 4) despite enzymatic removal of all N-linked carbohydrate chains. Thus, the increased electrophoretic mobility of APPβ in the presence of BFA cannot be accounted for solely by differences in N-linked carbohydrate processing.

In addition to N-linked glycosylation, however, APP undergoes a variety of posttranslational modifications, including the addition of O-linked carbohydrate chains. Therefore, we removed both N- and O-linked carbohydrate chains from immunoprecipitated APPβ by simultaneous digestion with Nglyc F, O-glycosidase, and neuraminidase. As shown, fully deglycosylated APPβ (Fig. 8 b, lane 2) comigrated with APPβ from BFA-treated NT2N neurons (Fig. 8 b, lane 3). Furthermore, combined BFA inhibition and deglycosylation (Fig. 8 b, lane 4) did not induce a greater mobility shift than either of these treatments alone (Fig. 8 b, lanes 2 and 4). Taken together, these results suggest that APPβ generated from BFA-treated NT2N neurons may represent β-secretase processing of immature (nonglycosylated) APPFL in a pre-Golgi compartment.

To further verify that β-secretase cleavage indeed occurs early in the biosynthetic pathway of NT2N neurons,
under these conditions (Fig. 9 suggesting that it is not transported to the Golgi apparatus at 15°C). Chyung et al. have employed an alternative nonpharmacological method to block protein transport from the ER to the Golgi. Incubation of cultured cells at 15°C continued to be produced intracellularly despite the effective temperature block. However, secreted APPβ was not detected in the medium at 15°C. Note that splitting intracellular APPβ samples recovered at 15°C for Endo H digestion decreased the yield to below the level of detection by this assay (data not shown). M, mature APPFL; I, immature APPFL; I', immature APPFL demonstrating a mobility shift due to Endo H sensitivity.

Figure 9. APPβ is generated in the ER/IC of NT2N neurons. Approximately 6 × 10^6 NT2N neurons were incubated at either 15°C or 37°C for 16 h. The cell lysates and media were harvested and immunoprecipitated with Karen. (A) The immunoprecipitates were then split, and half of the samples was treated with Endo H for 18 h, while the other half was mock digested. Subsequent to this step, the immunoprecipitates were separated by SDS-PAGE, transferred onto nitrocellulose replicas, and probed with the antibody Karen. The following observations serve to verify the effectiveness of the temperature block: (a) immature forms of APPFL (I and I') in the cell lysate retain Endo H sensitivity at 15°C; (b) mature glycosylated forms of APPβ (M) in the cell lysate are not detected at 15°C; and (c) secreted fragments are not detected in the conditioned medium at 15°C.

(B) Immunoprecipitates were separated by SDS-PAGE, transferred onto nitrocellulose replicas, and probed with antibody 53. APPβ was not affected by genetic targeting of APP to the ER (Fig. 10D), unlike inhibition with BFA that eliminates transport of all proteins from the ER to the Golgi, specific retrieval of full APP ectodomain is completely abolished (Fig. 9D). As expected, the immature APPFL was Endo H sensitive, while the mature forms of APPFL, having acquired posttranslational modifications after exiting the ER, were Endo H resistant. In addition, secreted forms of APP were not detected in cells maintained at 15°C, further substantiating the effectiveness of the temperature block. Significantly, continuous production of intracellular APPβ was observed at 15°C, despite the fact that the secretion of APP ectodomain is completely abolished (Fig. 9B). Taken together, these data support the ER/IC of NT2N neurons as a β-cleavage site.

A third approach was adopted to confirm that β-secretase cleavage indeed occurs in a pre-Golgi compartment of NT2N neurons. To accomplish this, we compared the processing of wild-type APP695 and APP695 bearing an ER-retrieval motif (APP695KK; Jackson et al., 1990, 1993) in the NT2N cells. We used recombinant Semliki Forest virus (SFV) vectors to express APP695KK, in which the third and fourth amino acids from the COOH terminus of APP are changed to lysines (i.e., APP695KK). Our previous studies have shown that despite high levels of SFV-mediated APP expression, SFV-infected NT2N cells display a high degree of fidelity in processing APP (Wertkin et al., 1993; Turner et al., 1996; Cook et al., 1997). Furthermore, we have found that cytopathic effects of SFV infection in NT2N cells as measured by LDH release do not develop until >48 h after infection (data not shown). Importantly, all if not a significant majority of APP695KK colocalize with calnexin, the ER marker, by immunofluorescence upon expression in NT2N neurons (Cook et al., 1997).

To determine whether or not APPβ can be produced from APP695KK, wild-type APP695 and APP695KK were separately expressed in NT2N neurons by infection with SFV vectors bearing these constructs. After infection, duplicate wells containing wild-type APP695-infected cells were also treated with 20 μg/ml BFA. The [35S]methionine-labeled cell lysates and the media were then sequentially immunoprecipitated with the antibodies 53 and Karen. Only the immature form of APPFL was detected from cells expressing APP695KK (Fig. 10B, compare lanes 1 and 3). Significantly, intracellular production and secretion of APPβ was not affected by genetic targeting of APP to the ER (Fig. 10A, lanes 3 and 6). Furthermore, we found that unlike inhibition with BFA that eliminates transport of all proteins from the ER to the Golgi, specific retrieval of full
length APP695ΔKK to the ER allowed the APPβ fragment generated in the ER/IC to be transported to the Golgi complex for modification before secretion (Fig. 10a, compare lanes 2 and 3 and lanes 5 and 6). This suggests that once the ER retention motif is cleaved from the APPβ fragment, it can then be transported to the Golgi complex for further maturation and subsequent secretion.

Discussion

APP serves as a substrate for a variety of proteolytic processing pathways, only some of which result in the production of Aβ (Selkoe, 1994). However, Aβ is the major component of senile plaques in the AD brain. Moreover, mutations in the APP gene associated with Familial Alzheimer’s disease alter APP processing and Aβ production in vitro (Citron et al., 1992; Cai et al., 1993; Suzuki et al., 1994). Thus, it will be important to determine the proteolytic events that lead to Aβ production and to identify the proteases responsible for each step as well as the sites of their action. In addition, it will be important to consider the cell type in which these processes occur. Non-neuronal cells favor the nonamyloidogenic α-secretase pathway. By contrast, neuronal cells exhibit increased β-secretase activity (Busciglio et al., 1993; Wertkin et al., 1993). To better understand APP processing in neurons, we have used the NT2N system for this study. We have previously shown that NT2N neurons express the isoform of APP expressed in freshly replenished medium, suggested that APPβ is generated intracellularly before secretion. Third, pulse-chase experiments demonstrated that the turnover of intracellular APPβ lags behind the turnover of newly synthesized APPFL, thereby confirming that APPβ is generated from APPFL inside NT2N neurons before secretion.

The detection of APPβ in the cell lysate of NT2N neurons, together with the presence of Aβ40 and Aβ42 (Turner et al., 1996), firmly established that an intracellular β-secretase pathway(s) must exist in these cells. At present, no other cell line has been reported to produce detectable levels of intracellular APPβ from endogenous or over-expressed wild-type APP (Seubert et al., 1993; Haass et al., 1995a; Thinakaran et al., 1996b). Only human kidney 293 cells stably transfected with APPsw cDNA yield the related APPβsw fragment from the cell lysates (Haass et al., 1995a; Martin et al., 1995). In these non-neuronal cells, however, treatment with BFA completely eliminates APPβsw and Aβ production (Haass et al., 1995a; Martin et al., 1995; Esmalmani et al., 1996). In contrast, NT2N neurons continue to produce APPβ and Aβ during treatment with BFA, implying that the subcellular site(s) of the β-secretase pathway is cell-type specific. Furthermore, this lack of inhibi-
tion of APPβ and Aβ production by BFA in NT2N cells suggests that at least one of the β-secretase pathways is localized to the ER/IC. Two additional independent means of testing this hypothesis (i.e., the use of 15°C temperature block and expression of APP bearing the dicyline ER retrieval signal) yielded consistent results.

Our data also suggest that the β-secretase pathway, but not the α-secretase pathway, occurs inside NT2N neurons. This view is based on the absence of APPα and p3 fragments in NT2N cell lysates. Of course, this observation alone cannot rule out the possibility of their presence below the level of detection by our assay. Nevertheless, these results imply that at least in this regard, NT2N neurons are similar to almost all other cell lines in which the enzymes of the α-secretase pathway are active at or near the cell surface. The uniqueness of intracellular processing in postmitotic neuronal cells such as the NT2N neurons lies in the fact that unlike non-neuronal cells, the amyloidogenic β-secretase pathway(s) is preferred. Accordingly, the level of Aβ secretion is much higher than that of p3 in postmitotic NT2N neurons.

The effect of the Swedish mutation on APP processing is interesting. Overexpression of APPsw in transfected, non-neuronal cells results in a 5-10-fold increase in Aβ secretion (Citron et al., 1992; Cai et al., 1993). Concomitant with this change, intracellular APPβsw is also detected in non-neuronal cells stably transfected with APPsw (Haass et al., 1995a, Thinakaran et al., 1996b). Transfection of wild-type APPsw in non-neuronal cells, however, fails to produce intracellular APPβ and results in the secretion of more p3 than Aβ (Thinakaran et al., 1996b). Thus, it appears that the introduction of the Swedish mutation shifts APP processing away from the α-secretase pathway to the β-secretase pathway. However, unlike NT2N neurons that may use multiple β-secretase pathways to produce both intracellular Aβ and APPβ, APPsw expressing non-neuronal cells use primarily the endosomal/lysosomal pathway or the Golgi-derived vesicles to generate intracellular Aβ and APPβsw, since treatment of these cells with BFA completely inhibits APPβsw and Aβ production (Haass et al., 1995a; Martin et al., 1995).

In view of the foregoing, three potential β-secretase pathways have been identified to date. Of these three, the endosomal/lysosomal pathway, which processes APP targeted to the cell surface after its reinternalization into endosomes and lysosomes, is the most ubiquitous. Both primary cultures of neuronal and non-neuronal cells, as well as multiple cell lines, use this pathway to produce Aβ. However, the contribution of endosomal/lysosomal processing to the overall production of Aβ is relatively minor since non-neuronal cells transfected with wild-type APP produce mostly p3 and very little Aβ (Haass et al., 1992a, b; Koo and Squazzo, 1994; Lai et al., 1995; Thinakaran et al., 1996b). In contrast, an alternative β-secretase pathway that produces Aβ in Golgi-derived vesicles is the most important for the production of Aβ in cells transfected with APPsw. Consistent with this view, transfection of an APPsw construct lacking the cytoplasmic tail, which eliminates reinternalization of cell surface APPsw, does not reduce the secretion of Aβ (Haass et al., 1995a; Essalmani et al., 1996). It is likely that the neuron-like NT2N cells also use this β-secretase pathway since neuronal cells (including hippocampal neurons and NT2N neurons) produce much higher levels of Aβ than p3. Finally, the third β-secretase pathway localized to the ER/IC appears to be preferentially used by postmitotic neuronal cells, since intracellular APPβ was not detected in several non-neuronal cell lines when treated with BFA.

The possibility of Aβ generation in the ER of NT2N neurons identifies these cells as a unique system in which to test the hypothesis that amyloidogenic processing of APP within that compartment plays an important role in the pathogenesis of AD. There is now strong evidence that mutations in both the APP gene and the recently identified presenilin genes cause AD by altering APP processing in ways that lead to the production of more amyloidogenic form of Aβ (i.e., Aβ42; Scheuner et al., 1996). Recently, in both non-neuronal and neuronal cells (including the NT2N neurons used in this study), the presenilin proteins have been localized to the ER (Cook et al., 1996; Kovacs et al., 1996; Thinakaran et al., 1996a). Thus, the identification of amyloidogenic processing that may occur within the ER of neurons raises the formal possibility that direct or indirect interaction may occur between the presenilins and APP. Furthermore, the mutations in the presenilin genes may alter this interaction in a manner that leads to increased production of Aβ42. Therefore, it will be particularly interesting to examine the effects of both Familial Alzheimer’s disease-linked mutations occurring in the APP as well as the presenilin genes on the processing of APP in the ER.

We thank Drs. T.E. Golde and J.Q. Trojanowski for critical review of the manuscript. We also thank Drs. D. Schenk, S. Gandy, and N. Suzuki for providing us with the antibody 192, antibody 369W, and the mAb Ban50, respectively. C.D. Page is thanked for providing some of the NT2N cells used in this study.

This work was supported by National Institutes of Health NIA grant AG-11542. Received for publication 14 February 1997 and in revised form 22 May 1997.

References

Arai, H., V.M.-Y. Lee, M. Messinger, B.D. Greenberg, D.E. Lowery, and J.Q. Trojanowski. 1991. Expression patterns of β-amyloid precursor protein (βAPP) in neural and nonneural human tissues from Alzheimer’s disease and control subjects. Ann. Neurol. 30:686–693.

Busciglio, J., D.H. Gabuzda, P. Matsudaara, and B.A. Yankner. 1993. Generation of β-amylloid in the secretory pathway in neuronal and nonneuronal cells. Proc. Natl. Acad. Sci. USA. 90:2092–2096.

Cai, X.-D., T.E. Golde, and S.G. Younkin. 1993. Release of excess amyloid β protein from a mutant amyloid β protein precursor. Science (Wash. DC). 299:514–516.

Citron, M., T. Oltersdorf, C. Haass, L. Conlongue, A.Y. Hung, P. Seubert, C. Vigo-Pelfrey, I. Lieberburg, and D.J. Selkoe. 1992. Mutation of the β-amylloid precursor protein in Alzheimer’s disease increases β-protein production. Nature (Lond.). 360:672–674.

Cook, D.G., J.C. Sung, T.E. Golde, K.M. Felsenstein, R.E. Wogczuk, R.E. Tanzi, J.Q. Trojanowski, V.M.-Y. Lee, and R.W. Doms. 1996. Expression and analysis of presenilin 1 in a human neuronal system: localization in cell bodies and dendrites. Proc. Natl. Acad. Sci. USA. 93:9223–9228.

Cook, D.G., M. Forman, J.C. Sung, S. Leight, D.L. Kison, T. Iwatsubo, V.M.-Y. Lee, and R.W. Doms. 1997. Alzheimer Aβ (42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Nat. Med. In press.

Doms, R.W., G. Russ, and J.W. Yewdell. 1989. Brefeldin A redistributes resident and itinerant Golgi proteins to the endoplasmic reticulum. J. Cell Biol. 109:61–72.

Esch, F.S., P.S. Keim, E.C. Beattie, R.W. Blacher, A.R. Culwell, T. Oltersdorf, D. McClure, and P.J. Ward. 1990. Cleavage of amyloid β-peptide during constitutive processing of its precursor. Science (Wash. DC). 243:1122–1124.

Essalmani, R., A.-F. Macq, L. Mercken, and J.-N. Octave. 1996. Misseense mutations associated with familial Alzheimer’s disease in Sweden lead to the pro-
duction of the amyloid peptide without internalization of its precursor. *Biochim. Biophys. Acta.* **1286**:89–98.  
Golde, T.E., S. Estus, L.H. Younkin, and S.G. Younkin. 1990. Expression of β-amyloid protein precursor mRNA: recognition of a novel alternatively spliced form and quantitation in Alzheimer's disease using PCR. *J. Neurosci. Res.* **25**:427–467.  
Golde, T.E., S. Estus, L.H. Younkin, D.J. Selkoe, and S.G. Younkin. 1992. Processing of the amyloid precursor protein to potentially amyloidogenic derivatives. *Science (Wash. DC).* **255**:726–730.  
Haass, C., E.H. Koo, A. Mellon, A.Y. Hung, and D.J. Selkoe. 1992. Targeting of cell-surface β-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. *Nature (Lond.)* **357**:500–503.  
Haass, C., M.G. Schlossmacher, A.Y. Hung, C. Vigo-Pelfrey, A. Mellon, B.L. Golde, I. Lieberburg, E.H. Koo, D. Schenk, D.B. Teplow, et al. 1996. β-Amyloid peptide is produced by cultured cells during normal metabolism. *Nature (Lond.)* **359**:322–325.  
Haass, C., C.A. Lemere, A. Capell, M. Citron, P. Seubert, D. Schenk, L. Lann, and D.J. Selkoe. 1995. The Swedish mutation causes early-onset Alzheimer's disease by β-secretase cleavage within the secretory pathway. *Nat. Med.* **1**:1291–1296.  
Haass, C., E.H. Koo, A. Capell, D.B. Teplow, and D.J. Selkoe. 1995. Polarized sorting of β-amyloid precursor protein and its proteolytic products in MDCK cells is regulated by two independent signals. *J. Cell Biol.* **126**:537–547.  
Higaki, J., D. Qion, Z. Zhong, and B. Cordell. 1995. Inhibition of β-amyloid formation identifies proteolytic precursors and subcellular site of catabolism. *Neuron.* **4**:651–659.  
Howland D.S., M.J. Savage, F.A. Huntress, R.E. Wallace, D.A. Schwartz, T. Haass, C., M.G. Schlossmacher, A.Y. Hung, C. Vigo-Pelfrey, A. Mellon, B.L. Golde, I. Lieberburg, E.H. Koo, D. Schenk, D.B. Teplow, et al. 1996. β-Amyloid peptide is produced by cultured cells during normal metabolism. *Neuron.* **18**:255:728–730.  
Kitaguchi, N., Y. Takahashi, Y. Tokushima, S. Shiojiri, and H. Ito. 1988. Novel monoclonal antibodies reactive to synthetic cerebrovascular amyloid peptide. *Nature (Lond.)* **331**:530–532.  
Kang, J., and B. Müller-Hill. 1990. Differential splicing of Alzheimer's disease amyloid A4 precursor mRNA in rat tissues: Pre-A4(95) mRNA is predominantly introduced in rod and rat brain. *Biochem. Biophys. Res. Commun.* **166**:1191–1202.  
Kang, J., H.-G. Lemaire, A. Unterbeck, M. Alsboum, C.L. Masters, K.H. Grzesik, G. Multhaup, K. Beyreuther, and B. Müller-Hill. 1987. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. *Nature (Lond.)* **325**:732–736.  
Kim, K.S., D.L. Miller, V.J. Sapienti, C.-M. Chen, C. Bai, I. Grundke-Iqbal, J.R. Currie, and H.M. Wisniewski. 1988. Production and characterization of monoclonal antibodies reactive to synthetic cerebrovascular amyloid peptide. *Neurosci. Res. Commun.* **2**:121–130.  
Kitaguchi, N., Y. Takahashi, Y. Tokushima, S. Shiojiri, and H. Ito. 1990. Inhibitory activity of monoclonal antibodies reactive to synthetic cerebrovascular amyloid peptide. *Neurosci. Res. Commun.* **2**:121–130.  
Knops, J., S. Gandy, P. Greengard, I. Lieberburg, S. Sinhas. 1993. Serine phosphorylation of the secreted extracellular domain of APP. *Biochem. Biophys. Res. Commun.* **197**:380–385.  
Koo, E.H., and S. Squazzo. 1994. Evidence that production and release of amyloid β-protein involves the endocytic pathway. *J. Biol. Chem.* **269**:17386–17390.  
Kovacs, D.M., H.J. Faussett, K.J. Page, T.-W. Kim, R.D. Moir, D.E. Merriam, R.D. Hollister, O.G. Hallmark, R. Mancini, K.M. Felsenstein, et al. 1996. Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells. *Nat. Med.* **2**:224–229.  
Lai, A., S. Sisodia, and I.S. Trowbridge. 1995. Characterization of sorting signals in the β-amyloid precursor protein cytoplasmic domain. *J. Biol. Chem.* **270**:3566–3573.  
Lijjestrom, P., and H. Garoff. 1991. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. *Biotechnology (NY).* **9**:1356–1361.  
Lippincott-Schwartz, J.L., L.C. Yuan, S.J. Banfaccino, and R.D. Klauser. 1989. Rapid redistribution of Golgi proteins into the endoplasmic reticulum in cells treated with Brefeldin A: evidence for membrane cycling from Golgi to ER. *Cell.* **56**:801–813.  
Martin, B.L., G. Schrader-Fischer, J. Busciglio, M. Duke, P. Paganoet, and B.A. Young. 1995. Intracellular accumulation of β-amyloid in cells expressing the Swedish mutant amyloid precursor protein. *J. Biol. Chem.* **270**:26727–26730.  
Nordstedt, C., G. Caporaso, J. Thyberg, S. Gandy, and P. Greengard. 1993. Identification of the Alzheimer β/Aβ amyloid precursor protein in chitin-coated vesicles purified from PC12 cells. *J. Biol. Chem.* **268**:608–612.  
Oltermos, T., P.J. Ward, T. Henriksson, E.C. Beattie, R. Neve, I. Lieberburg, and L.C. Fritz. 1990. The Alzheimer amyloid precursor protein. Identification of a stable intermediate in the biosynthetic/degradative pathway. *J. Biol. Chem.* **265**:4492–4497.  
Pelham, H.R. 1991. Multiple targets for Brefeldin A. *Cell.* **67**:449–451.